Nintedanib Sandoz

Nintedanib, the active ingredient in Nintedanib Sandoz, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination therapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with reliable logistics.

Nintedanib is used to target fibrotic and oncologic pathways in several serious lung conditions. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances antitumor efficacy when used with standard chemotherapy.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: transient feeling of sickness. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of arterial thromboembolism.

When prescribing Nintedanib, clinicians should consider several safety measures. - Liver function monitoring: assess ALT/AST before initiation and periodically during therapy. - Gastrointestinal management: treat diarrhea promptly and maintain hydration. - Cardiovascular assessment: evaluate arterial thromboembolism risk prior to use. - Drug interactions: review concomitant medicines that affect CYP3A4 activity. - Pregnancy and lactation: avoid unless benefits outweigh potential risks and specialist advice is obtained. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Nintedanib can interact with other medicines, affecting its concentration or increasing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nintedanib levels, increasing toxicity risk. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase exposure. - P‑glycoprotein substrates (e.g., digoxin): possible altered plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels.